Daren Tompkins, MD
Family Medicine · Granbury, TXNPI 1922177583
Payments from drug & device makers
Across 229 payments — averaging $16.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$706
- Novo Nordisk$630
- Amgen$480
- Mylan Specialty L.p.$194
- Pfizer$152
- Astellas Pharma US Inc$143
- plus $2K from 30 others
What the payments were for
- Food & beverage$3,851100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 44 | $706 |
| Novo Nordisk | 46 | $630 |
| Amgen | 28 | $480 |
| Mylan Specialty L.p. | 10 | $194 |
| Pfizer | 8 | $152 |
| Astellas Pharma US Inc | 7 | $143 |
| Supernus Pharmaceuticals, Inc. | 6 | $138 |
| Johnson & Johnson(2 entities) | 3 | $116 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $114 |
| AstraZeneca | 7 | $107 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $88 |
| Amarin Pharma, Inc. | 6 | $88 |
| GSK | 5 | $88 |
| Lilly USA, LLC | 5 | $77 |
| Ironshore Pharmaceuticals Inc. | 4 | $75 |
| Cranial Technologies, Inc | 4 | $70 |
| Adlon Therapeutics L.p. | 3 | $68 |
| Boehringer Ingelheim | 3 | $68 |
| Exact Sciences | 3 | $58 |
| Dexcom, Inc. | 3 | $57 |
| Otsuka America Pharmaceutical, Inc. | 3 | $41 |
| Planmeca USA, Inc. | 2 | $41 |
| Alnylam Pharmaceuticals Inc. | 2 | $32 |
| Teva Pharmaceuticals USA, Inc. | 2 | $25 |
| Nevro Corp. | 1 | $25 |
| Novartis | 1 | $23 |
| Abbott | 1 | $22 |
| Antares Pharma, Inc. | 1 | $22 |
| Nestle Healthcare Nutrition Inc. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Acerus Pharmaceuticals Corporation | 1 | $14 |
| Alfasigma USA, Inc. | 1 | $14 |
| Vistapharm, Inc. | 1 | $12 |
| Phathom Pharmaceuticals, Inc. | 1 | $12 |
| Eisai Inc. | 1 | $12 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$3,851 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 155 | $250,263 |
| EliquisApixaban | 81 | $92,645 |
| JardianceEmpagliflozin | 69 | $79,318 |
| FarxigaDapagliflozin Propanediol | 35 | $43,708 |
| JanuviaSitagliptin Phosphate | 24 | $32,416 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $31,525 |
| TrulicityDulaglutide | 24 | $30,862 |
| VascepaIcosapent Ethyl | 31 | $28,006 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $25,965 |
| MounjaroTirzepatide | 11 | $19,900 |
| XareltoRivaroxaban | 20 | $18,373 |
| VraylarCariprazine Hcl | 12 | $18,014 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $13,414 |
| MyrbetriqMirabegron | 11 | $12,335 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $12,244 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $630 | $250,263155 claims |
| PfizerEliquis | $152 | $92,64581 claims |
| Boehringer IngelheimJardiance | $68 | $79,31869 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $107 | $55,95246 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $77 | $50,76135 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $88 | $37,45843 claims |
| AbbVieVraylar, Linzess, Synthroid | $706 | $30,66383 claims |
| Johnson & JohnsonXarelto | $116 | $18,37320 claims |
| Astellas Pharma US IncMyrbetriq | $143 | $12,33511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Granbury
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.